Elanco Animal Health Boosts FY23 Adj. EPS, Revenue Outlook As Q3 Results Top Estimates

RTTNews | 660 dias atrás
Elanco Animal Health Boosts FY23 Adj. EPS, Revenue Outlook As Q3 Results Top Estimates

(RTTNews) - Elanco Animal Health Inc. (ELAN) reported Tuesday a net loss for the third quarter of $1.10 billion or $2.22 per share, sharply wider than $65.0 million or $0.13 per share in the prior-year quarter.

Excluding items, adjusted earnings for the quarter was $0.18 per share, compared to $0.17 per share in the year-ago quarter.

Total revenues for the quarter increased 4 percent to $1.07 billion from $1.03 billion in the same quarter last year. Revenues were up 5 percent excluding the unfavorable impact from foreign exchange rates.

On average, analysts polled by Thomson Reuters expected the company to report earnings of $0.12 per share on revenues of $1.04 billion for the quarter. Analysts' estimates typically exclude special items.

Looking ahead to the fourth quarter, the company expects a loss in a range of $0.23 to $0.17 per share and adjusted earnings in a range of $0.07 to $0.13 per share on revenues between $978 million and $1.02 billion, with constant currency revenue growth of 1 to 4 percent.

Analysts expect earnings of $0.11 per share on revenues of $1.02 billion for the quarter.

For fiscal 2023, the company now projects a loss in a range of $2.43 to $2.37 per share and adjusted earnings in a range of $0.88 to $0.94 per share on revenues between $4.36 billion and $4.40 billion, with constant currency revenue to be between flat and a 1 percent increase.

Previously, the company expected a loss in the range of $0.34 to $0.26 per share and adjusted earnings in the range of $0.80 to $0.89 per share on revenues between $4.35 billion and $4.10 billion.

The Street is looking for earnings of $0.85 per share on revenues of $4.37 billion for the year.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

Etiquetas: ELAN
read more
Elanco Animal Health Closes Sale Of Aqua Business To Merck Animal Health

Elanco Animal Health Closes Sale Of Aqua Business To Merck Animal Health

Elanco Animal Health, Inc. (ELAN) announced Tuesday it has completed the divestiture of its aqua business to Merck Animal Health (MRK) for approximately $1.3 billion in cash, with approximately $1.05 billion to $1.1 billion in net proceeds available for debt paydown in the third quarter of 2024.
RTTNews | 415 dias atrás
Elanco's Canine Parvovirus Treatment Gets USDA License

Elanco's Canine Parvovirus Treatment Gets USDA License

Elanco Animal Health Inc. announced that the U.S. Department of Agriculture or USDA has issued a conditional license for its Canine Parvovirus Monoclonal Antibody. The company expects to begin shipping Canine Parvovirus Monoclonal Antibody in the coming weeks, pending individual state approvals. The targeted single-dose monoclonal antibody is the first and only approved targeted therapeutic...
RTTNews | 848 dias atrás
FDA Approves First Drug For Anemia In Cats With CKD

FDA Approves First Drug For Anemia In Cats With CKD

The U.S. Food and Drug Administration conditionally approved Elanco US Inc.'s Varenzin-CA1 (molidustat oral suspension) for treating anemia in cats with chronic kidney disease or CKD. It is the first drug for the control of nonregenerative anemia associated with CKD in cats. Varenzin-CA1 works by helping to increase production of erythropoietin in the kidney, which in turn stimulates the bone mar
RTTNews | 849 dias atrás
DAX Retreats After Firm Start, Down Marginally

DAX Retreats After Firm Start, Down Marginally

After opening on a strong note thanks to easing AI slowdown fears after Nvidia's impressive results, the German market retreated and slipped into negative territory on Thursday. Despite paring some early gains, auto stocks remain fairly well up in positive territory.
RTTNews | 23 minutos atrás
Sensex, Nifty Retreat On US Tariff Worries

Sensex, Nifty Retreat On US Tariff Worries

Indian shares fell sharply on Thursday as traders waited to see how New Delhi responds to pressure from Washington to stop buying Russian oil after the 50 percent tariffs levied by the U.S. on Indian goods came into effect on Wednesday.
RTTNews | 43 minutos atrás
Bank Of Korea Stands Pat On Rates, Lifts 2025 Growth Outlook

Bank Of Korea Stands Pat On Rates, Lifts 2025 Growth Outlook

The Bank of Korea left its interest rate unchanged on Thursday as economic growth improved moderately despite high uncertainty surrounding the outlook. The Monetary Policy Board decided to hold the Base Rate at 2.50 percent. The central bank had previously lowered the benchmark rate by a quarter-point each in May and February.
RTTNews | 50 minutos atrás